Drug intelligence / Profile preview

VTI-003

Development stage: Unknown
Lead developer: VISUS Health IT
Modality: Small Molecules, Peptides
Administration: Ophthalmic

Overview

VTI-003 is an investigational **synthetic peptide** ophthalmic drug candidate being developed by VISUS Health IT GmbH and associated publicly with Visus Therapeutics. Publicly available information is limited, but the program has been described as a **preclinical** asset for **corneal wound healing**, including potential use in **post-surgical eye care** and **ocular surface disease**. Its precise molecular target, detailed mechanism of action, dosage form, and route of administration have not been clearly disclosed in accessible sources.

Beyond the preview

Go deeper on VTI-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VTI-003.

Explore the full profile